Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Issued (2022 - 2025)

Historic Shares Issued for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $38.2 million.

  • BioXcel Therapeutics' Shares Issued rose 808715.2% to $38.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.4 million, marking a year-over-year increase of 10071.32%. This contributed to the annual value of $39.7 million for FY2024, which is 4681.86% up from last year.
  • Per BioXcel Therapeutics' latest filing, its Shares Issued stood at $38.2 million for Q3 2025, which was up 808715.2% from $140000.0 recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Shares Issued registered a high of $38.2 million during Q3 2025, and its lowest value of $48000.0 during Q3 2022.
  • In the last 4 years, BioXcel Therapeutics' Shares Issued had a median value of $4.7 million in 2023 and averaged $11.4 million.
  • Data for BioXcel Therapeutics' Shares Issued shows a peak YoY increase of 808715.2% (in 2025) and a maximum YoY decrease of 4762.74% (in 2025) over the last 5 years.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Shares Issued stood at $50000.0 in 2022, then surged by 4650.0% to $2.4 million in 2023, then skyrocketed by 194.78% to $7.0 million in 2024, then soared by 446.12% to $38.2 million in 2025.
  • Its Shares Issued was $38.2 million in Q3 2025, compared to $140000.0 in Q2 2025 and $14.0 million in Q1 2025.